Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
PLoS One ; 13(11): e0206534, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30395586

RESUMO

BACKGROUND: Human adult adipose-derived stem cells (hADSCs) have become the most promising cell source for regenerative medicine. However the prolonged ex vivo expansion periods required to obtain the necessary therapeutic dose promotes progressive senescence, with the concomitant reduction of their therapeutic potential. AIM AND SCOPE: A better understanding of the determinants of hADSC senescence is needed to improve biosafety while preserving therapeutic efficiency. Here, we investigated the association between deregulation of the imprinted DLK1-DIO3 region and replicative senescence in hADSC cultures. METHODS: We compared hADSC cultures at short (PS) and prolonged (PL) passages, both in standard and low [O2] (21 and 3%, respectively), in relation to replicative senescence. hADSCs were evaluated for expression alterations in the DLK1-DIO3 region on chromosome 14q32, and particularly in its main miRNA cluster. RESULTS: Comparison of hADSCs cultured at PL or PS surprisingly showed a quite significant fraction (69%) of upregulated miRNAs in PL cultures mapping to the imprinted 14q32 locus, the largest miRNA cluster described in the genome. In agreement, expression of the lncRNA MEG3 (Maternally Expressed 3; Meg3/Gtl2), cultured at 21 and 3% [O2], was also significantly higher in PL than in PS passages. During hADSC replicative senescence the AcK16H4 activating mark was found to be significantly associated with the deregulation of the entire DLK1-DIO3 locus, with a secondary regulatory role for the methylation of DMR regions. CONCLUSION: A direct relationship between DLK1-DIO3 deregulation and replicative senescence of hADSCs is reported, involving upregulation of a very significant fraction of its largest miRNA cluster (14q32.31), paralleled by the progressive overexpression of the lncRNA MEG3, which plays a central role in the regulation of Dlk1/Dio3 activation status in mice.


Assuntos
Impressão Genômica , Peptídeos e Proteínas de Sinalização Intercelular/genética , Iodeto Peroxidase/genética , Proteínas de Membrana/genética , Células-Tronco Mesenquimais/citologia , Células-Tronco Mesenquimais/metabolismo , RNA Longo não Codificante/genética , RNA Longo não Codificante/metabolismo , Animais , Proteínas de Ligação ao Cálcio , Proliferação de Células/genética , Células Cultivadas , Senescência Celular/genética , Cromossomos Humanos Par 14/genética , Epigênese Genética , Regulação da Expressão Gênica , Humanos , Camundongos , MicroRNAs/genética , Regulação para Cima
2.
Stem Cell Res Ther ; 7(1): 100, 2016 Jul 30.
Artigo em Inglês | MEDLINE | ID: mdl-27472922

RESUMO

BACKGROUND: The inability of the adult mammalian heart to replace cells lost after severe cardiac injury compromises organ function. Although the heart is one of the least regenerative organs in the body, evidence accumulated in recent decades indicates a certain degree of renewal after injury. We have evaluated the role of cardiac Bmi1 (+) progenitor cells (Bmi1-CPC) following acute myocardial infarction (AMI). METHODS: Bmi1 (Cre/+);Rosa26 (YFP/+) (Bmi1-YFP) mice were used for lineage tracing strategy. After tamoxifen (TM) induction, yellow fluorescent protein (YFP) is expressed under the control of Rosa26 regulatory sequences in Bmi1 (+) cells. YFP(+) cells were tracked following myocardial infarction. Additionally, whole transcriptome analysis of isolated YFP(+) cells was performed in unchallenged hearts and after myocardial infarction. RESULTS: Deep-sequencing analysis of Bmi1-CPC from unchallenged hearts suggests that this population expresses high levels of pluripotency markers. Conversely, transcriptome evaluation of Bmi1-CPC following AMI shows a rich representation of genes related to cell proliferation, movement, and cell cycle. Lineage-tracing studies after cardiac infarction show that the progeny of Bmi1-expressing cells contribute to de novo cardiomyocytes (CM) (13.8 ± 5 % new YFP(+) CM compared to 4.7 ± 0.9 % in age-paired non-infarcted hearts). However, apical resection of TM-induced day 1 Bmi1-YFP pups indicated a very minor contribution of Bmi1-derived cells to de novo CM. CONCLUSIONS: Cardiac Bmi1 progenitor cells respond to cardiac injury, contributing to the generation of de novo CM in the adult mouse heart.


Assuntos
Infarto do Miocárdio/genética , Miócitos Cardíacos/citologia , Complexo Repressor Polycomb 1/genética , Proteínas Proto-Oncogênicas/genética , Regeneração/genética , Células-Tronco/citologia , Transcriptoma , Animais , Proteínas de Bactérias/genética , Proteínas de Bactérias/metabolismo , Diferenciação Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Rastreamento de Células , Modelos Animais de Doenças , Feminino , Regulação da Expressão Gênica , Humanos , Proteínas Luminescentes/genética , Proteínas Luminescentes/metabolismo , Masculino , Camundongos , Camundongos Transgênicos , Infarto do Miocárdio/metabolismo , Infarto do Miocárdio/patologia , Miocárdio/metabolismo , Miocárdio/patologia , Miócitos Cardíacos/efeitos dos fármacos , Miócitos Cardíacos/metabolismo , Complexo Repressor Polycomb 1/agonistas , Complexo Repressor Polycomb 1/metabolismo , Proteínas Proto-Oncogênicas/agonistas , Proteínas Proto-Oncogênicas/metabolismo , RNA não Traduzido/genética , RNA não Traduzido/metabolismo , Regeneração/efeitos dos fármacos , Transdução de Sinais , Células-Tronco/efeitos dos fármacos , Células-Tronco/metabolismo , Tamoxifeno/farmacologia
3.
Stem Cell Res Ther ; 6: 205, 2015 Oct 26.
Artigo em Inglês | MEDLINE | ID: mdl-26503423

RESUMO

INTRODUCTION: The mammalian adult heart maintains a continuous, low cardiomyocyte turnover rate throughout life. Although many cardiac stem cell populations have been studied, the natural source for homeostatic repair has not yet been defined. The Polycomb protein BMI1 is the most representative marker of mouse adult stem cell systems. We have evaluated the relevance and role of cardiac Bmi1 (+) cells in cardiac physiological homeostasis. METHODS: Bmi1 (CreER/+);Rosa26 (YFP/+) (Bmi1-YFP) mice were used for lineage tracing strategy. After tamoxifen (TM) induction, yellow fluorescent protein (YFP) is expressed under the control of Rosa26 regulatory sequences in Bmi1 (+) cells. These cells and their progeny were tracked by FACS, immunofluorescence and RT-qPCR techniques from 5 days to 1 year. RESULTS: FACS analysis of non-cardiomyocyte compartment from TM-induced Bmi1-YFP mice showed a Bmi1 (+)-expressing cardiac progenitor cell (Bmi1-CPC: B-CPC) population, SCA-1 antigen-positive (95.9 ± 0.4 %) that expresses some stemness-associated genes. B-CPC were also able to differentiate in vitro to the three main cardiac lineages. Pulse-chase analysis showed that B-CPC remained quite stable for extended periods (up to 1 year), which suggests that this Bmi1 (+) population contains cardiac progenitors with substantial self-maintenance potential. Specific immunostaining of Bmi1-YFP hearts serial sections 5 days post-TM induction indicated broad distribution of B-CPC, which were detected in variably sized clusters, although no YFP(+) cardiomyocytes (CM) were detected at this time. Between 2 to 12 months after TM induction, YFP(+) CM were clearly identified (3 ± 0.6 % to 6.7 ± 1.3 %) by immunohistochemistry of serial sections and by flow cytometry of total freshly isolated CM. B-CPC also contributed to endothelial and smooth muscle (SM) lineages in vivo. CONCLUSIONS: High Bmi1 expression identifies a non-cardiomyocyte resident cardiac population (B-CPC) that contributes to the main lineages of the heart in vitro and in vivo.


Assuntos
Coração/fisiologia , Miócitos Cardíacos/metabolismo , Complexo Repressor Polycomb 1/fisiologia , Proteínas Proto-Oncogênicas/fisiologia , Regeneração , Animais , Biomarcadores/metabolismo , Transplante de Medula Óssea , Diferenciação Celular , Células Cultivadas , Feminino , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Células-Tronco Embrionárias Murinas/metabolismo , Ratos Wistar
4.
Cell Signal ; 19(10): 2098-105, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17658243

RESUMO

15-deoxy-Delta(12,14)-prostaglandin-J(2) (15d-PGJ(2)) is a peroxisome-activated proliferator receptor-gamma (PPARgamma) agonist which contains an alpha,beta-unsaturated electrophilic ketone involved in nucleophilic addition reactions to thiols. Here we studied its effect on hypoxia-inducible factor-1alpha (HIF-1alpha) in human proximal tubular cells HK-2. 15d-PGJ(2) induced stabilization of HIF-1alpha protein, without affecting HIF-1alpha mRNA levels or proteasome activity, leading to its nuclear accumulation and activation of HIF-induced transcription. Accumulation of HIF-1alpha was unaffected by selective PPARgamma blockade nor mimicked by the PPARgamma agonists ciglitazone and 9,10-dihydro-15d-PGJ(2). N-acetylcysteine, reduced glutathione (GSH) or dithiothreitol (i.e. agents that act as thiol reducing agents and/or increase the GSH content), but not reactive oxygen species (ROS) scavengers, prevented 15d-PGJ(2)-induced HIF-1alpha accumulation whereas the inhibitor of GSH synthesis buthionine sulfoximine cooperated with 15d-PGJ(2) to accumulate HIF-1alpha. Finally, HIF-1alpha expression was increased by the electrophilic alpha,beta-unsaturated compounds acrolein and PGA(2), but not by 9,10-dihydro-15d-PGJ(2), which lacks the electrophilic cyclopentenone moiety. Taken together, these results point out to a new mechanism to increase pharmacologically the cell levels of HIF-1alpha through the electrophilic reaction of alpha,beta-unsaturated ketones with thiol groups.


Assuntos
Subunidade alfa do Fator 1 Induzível por Hipóxia/biossíntese , Túbulos Renais Proximais/metabolismo , Prostaglandina D2/análogos & derivados , Antioxidantes/farmacologia , Linhagem Celular , Núcleo Celular/metabolismo , Glutationa/antagonistas & inibidores , Glutationa/farmacologia , Humanos , Subunidade alfa do Fator 1 Induzível por Hipóxia/genética , Rim/efeitos dos fármacos , Rim/metabolismo , Túbulos Renais Proximais/efeitos dos fármacos , PPAR gama/agonistas , PPAR gama/metabolismo , Prostaglandina D2/antagonistas & inibidores , Prostaglandina D2/química , Prostaglandina D2/farmacologia , Inibidores de Proteassoma , Espécies Reativas de Oxigênio/metabolismo , Substâncias Redutoras/farmacologia , Compostos de Sulfidrila/farmacologia , Transcrição Gênica
5.
Ther Drug Monit ; 25(2): 221-8, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12657918

RESUMO

Tegafur, a prodrug of 5-fluorouracil (5-FU), is an oral fluorouracil antitumor drug used for the management of adenocarcinomas. It has an efficacy similar to that of intravenous 5-FU, with potential advantages in terms of convenience and quality of life for the patient and cost-effectiveness as compared with intravenous chemotherapy. The authors developed a high-performance liquid chromatography (HPLC) assay for the determination of tissue or plasma tegafur and 5-FU concentration in a single step extraction and a single HPLC injection. The retention times of 5-FU and tegafur were 5 and 16.5 minutes, respectively, and the internal standard retention times were 11.5 and 17.5 minutes for 5-bromouracil (5-BU) and beta-hydroxyethyltheophylline, respectively. The limit of quantification was 0.0125 microg/mL for 5-FU and 0.05 microg/mL for tegafur. The assay had good recovery (96.5% +/- 9.45% and 97.5% +/- 7.89% for 5-FU in plasma and tissue, respectively, and 88.5% +/- 12.17% and 104.9% +/- 8.77% for tegafur in plasma and tissue, respectively). Precision was good: the within-day and between-day standard deviation of the mean (RSD) for 5-FU (0.0125-5 microg/mL) and tegafur (0.5-150 microg/mL) was always <8%. The authors conclude that the method described here is ideally suited for the therapeutic monitoring of 5-FU and tegafur.


Assuntos
Antimetabólitos Antineoplásicos/sangue , Fluoruracila/análise , Pró-Fármacos/metabolismo , Tegafur/análise , Cromatografia Líquida de Alta Pressão/métodos , Fluoruracila/sangue , Humanos , Tegafur/sangue , Distribuição Tecidual
6.
Bol. méd. Hosp. Infant. Méx ; 57(8): 444-8, ago. 2000. ilus
Artigo em Espanhol | LILACS | ID: lil-286267

RESUMO

Introducción. Candidiosis sistémica tiene una mortalidad de 60-80 por ciento, aumenta cuando es causada por Candida sp. resistente a los antimicóticos convencionales. Objetivo: presentar la evolución clínica de un caso pediátrico de candidiosis sistémica. Caso clínico. Niña de 3 años de edad con diagnóstico en marzo de 1996 de linfoma no Hodgkin. Con quimioterapia de consolidación y rescate. Ingresó el 12 de junio de 1998 con neutropenia grave, afebril, y cistitis hemorrágica. Se manejó inicialmente con antibióticos de amplio espectro. Al séptimo día, con 6 días febril se inició anfotericina B. Al noveno día se observaron abscesos en dorso de mano izquierda, pliegue de codo y antebrazo derecho. Los cultivos de aspirado de los abscesos, hemocultivo central/periférico, urocultivo y coprocultivo reportaron levaduras. El aislamiento en tubo germinativo fue negativo. El ultrasonido y la tomografía axial computada abdominal reportaron lesiones parenquimatosas en hígado, con múltiples lesiones hipoecoicas en bazo, riñón y músculos paravertebrales. Confirmándose por biopsia de bazo. Mediante API 20 C AUX se identificó Candida famata. La sensibilidad reportó resistencia a anfotericina B 2 µg/mL (normal: £ 1), fluconazol 64 µg/mL (normal: £ 16) y susceptible a 5-fluocitosina 12.5 µg/mL (normal: £ 25). Se adicionó rifampicina y 5-fluocitocina. El control tomográfico demostró disminución del tamaño de los abscesos. Falleció por un evento de choque séptico asociado a Staphylococcus epidermidis. La autopsia reportó persistencia de levaduras. Conclusiones. La respuesta a la anfotericina B es pobre cuando se trata de Candida diferente a Candida albicans.


Assuntos
Humanos , Feminino , Pré-Escolar , Anfotericina B , Candidíase/diagnóstico , Resistência Microbiana a Medicamentos , Fluconazol , Fígado/microbiologia , Rim/microbiologia , Choque Séptico , Baço/microbiologia , Candida/patogenicidade , Linfoma não Hodgkin , Neutropenia , Especificidade da Espécie
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA